PMID- 28382109
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240324
IS  - 1756-2856 (Print)
IS  - 1756-2864 (Electronic)
IS  - 1756-2856 (Linking)
VI  - 10
IP  - 2
DP  - 2017 Feb
TI  - The efficacy of lacosamide as monotherapy and adjunctive therapy in focal 
      epilepsy and its use in status epilepticus: clinical trial evidence and 
      experience.
PG  - 103-126
LID - 10.1177/1756285616675777 [doi]
AB  - Lacosamide (LCM) is approved for anticonvulsive treatment in focal epilepsy and 
      exhibits its function through the slow inactivation of voltage-gated sodium 
      channels (VGSCs). LCM shows comparable efficacy with other antiepileptic drugs 
      (AEDs) licensed in the last decade: in three randomized placebo-controlled 
      trials, significant median seizure reduction rates of 35.2% for 200 mg/day, 
      36.4-39% for 400 mg/day and 37.8-40% for 600 mg/day were reported. Likewise, 50% 
      responder rates were 38.3-41.1% for 400 mg/day and 38.1-41.2% for 600 mg/day. 
      Similar rates were reported in post-marketing studies. The main adverse events 
      (AEs) are dizziness, abnormal vision, diplopia and ataxia. Overall, LCM is well 
      tolerated and has no clinically-relevant drug-drug interactions. Due to the 
      drug's intravenous availability, its use in status epilepticus (SE) is 
      increasing, and the available data are promising.
FAU - Bauer, Sebastian
AU  - Bauer S
AD  - Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, 
      Goethe-University, Frankfurt am Main, Germany Epilepsy Center Hessen and 
      Department of Neurology, Philipps-University, Marburg, Germany.
FAU - Willems, Laurent M
AU  - Willems LM
AD  - Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, 
      Goethe-University, Frankfurt am Main, Germany.
FAU - Paule, Esther
AU  - Paule E
AD  - Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, 
      Goethe-University, Frankfurt am Main, Germany.
FAU - Petschow, Christine
AU  - Petschow C
AD  - Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, 
      Goethe-University, Frankfurt am Main, Germany.
FAU - Zollner, Johann Philipp
AU  - Zollner JP
AD  - Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, 
      Goethe-University, Frankfurt am Main, Germany.
FAU - Rosenow, Felix
AU  - Rosenow F
AD  - Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, 
      Goethe-University, Frankfurt am Main, Germany Epilepsy Center Hessen and 
      Department of Neurology, Philipps-University, Marburg, Germany.
FAU - Strzelczyk, Adam
AU  - Strzelczyk A
AD  - Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, 
      Goethe-University, Frankfurt am Main, Germany Epilepsy Center Hessen and 
      Department of Neurology, Philipps-University, Marburg, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20161129
PL  - England
TA  - Ther Adv Neurol Disord
JT  - Therapeutic advances in neurological disorders
JID - 101480242
PMC - PMC5367645
OTO - NOTNLM
OT  - epilepsy
OT  - lacosamide
OT  - monotherapy
OT  - partial-onset
OT  - seizure
COIS- Conflict of interest statement: Dr Bauer, E. Paule, C. Petschow and J.P. Zollner 
      have nothing to disclose. Dr Willems reports travel support from Eisai, outside 
      the submitted work. Dr Rosenow reports personal fees from Eisai, grants and 
      personal fees from UCB, grants and personal fees from Desitin Pharma, personal 
      fees and other from Novartis, personal fees from Medtronic, personal fees from 
      Cerbomed, personal fees from ViroPharma and Shire, grants from European Union, 
      grants from Deutsche Forschungsgemeinschaft, outside the submitted work. Dr 
      Strzelczyk reports personal fees and grants from Bayer HealthCare, Boehringer 
      Ingelheim, Desitin Arzneimittel, Eisai, Pfizer, Sage Therapeutics, and UCB 
      Pharma, outside the submitted work. We confirm that we have read the Journal's 
      position on issues involved in ethical publication and affirm that this report is 
      consistent with those guidelines.
EDAT- 2017/04/07 06:00
MHDA- 2017/04/07 06:01
PMCR- 2017/02/01
CRDT- 2017/04/07 06:00
PHST- 2017/04/07 06:00 [entrez]
PHST- 2017/04/07 06:00 [pubmed]
PHST- 2017/04/07 06:01 [medline]
PHST- 2017/02/01 00:00 [pmc-release]
AID - 10.1177_1756285616675777 [pii]
AID - 10.1177/1756285616675777 [doi]
PST - ppublish
SO  - Ther Adv Neurol Disord. 2017 Feb;10(2):103-126. doi: 10.1177/1756285616675777. 
      Epub 2016 Nov 29.